BRPI0414864A - composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida - Google Patents

composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida

Info

Publication number
BRPI0414864A
BRPI0414864A BRPI0414864-9A BRPI0414864A BRPI0414864A BR PI0414864 A BRPI0414864 A BR PI0414864A BR PI0414864 A BRPI0414864 A BR PI0414864A BR PI0414864 A BRPI0414864 A BR PI0414864A
Authority
BR
Brazil
Prior art keywords
combination
mycophenolic acid
pharmaceutical composition
rapamide
mycophenolate sodium
Prior art date
Application number
BRPI0414864-9A
Other languages
English (en)
Inventor
Dieter Becker
Carsten Buerger
Gilles Feutren
Patrice Guitard
Andrea Kramer
Nicoletta Loggia
Christian-Peter Luftensteiner
J Rg Ogorka
Harald Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0323202A external-priority patent/GB0323202D0/en
Priority claimed from GB0323598A external-priority patent/GB0323598D0/en
Priority claimed from GB0329852A external-priority patent/GB0329852D0/en
Priority claimed from GB0405902A external-priority patent/GB0405902D0/en
Priority claimed from GB0410714A external-priority patent/GB0410714D0/en
Priority claimed from GB0419356A external-priority patent/GB0419356D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0414864A publication Critical patent/BRPI0414864A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

"COMPOSIçãO FARMACêUTICA MULTIPARTICULADA COMPREENDENDO áCIDO MICOFENóLICO OU MICOFENOLATO DE SóDIO E COMBINAçãO COM RAPAMICINA". A presente invenção refere-se a uma composição inusitada de ácido micofenólico, um sal ou pró-fármaco do mesmo, e uma combinação fixa de ácido micofenólico, um sal ou pró-fármaco do mesmo, e rapamicina ou um derivado de rapamicina.
BRPI0414864-9A 2003-10-03 2004-10-01 composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida BRPI0414864A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0323202A GB0323202D0 (en) 2003-10-03 2003-10-03 Organic compounds
GB0323598A GB0323598D0 (en) 2003-10-08 2003-10-08 Organic compounds
GB0329852A GB0329852D0 (en) 2003-12-23 2003-12-23 Organic compounds
GB0405902A GB0405902D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0410714A GB0410714D0 (en) 2004-05-13 2004-05-13 Organic compounds
GB0419356A GB0419356D0 (en) 2004-08-31 2004-08-31 Organic compounds
PCT/EP2004/010998 WO2005034916A1 (en) 2003-10-03 2004-10-01 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin

Publications (1)

Publication Number Publication Date
BRPI0414864A true BRPI0414864A (pt) 2006-11-28

Family

ID=34437795

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414864-9A BRPI0414864A (pt) 2003-10-03 2004-10-01 composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida

Country Status (11)

Country Link
US (1) US20070036857A1 (pt)
EP (1) EP1670437A1 (pt)
JP (1) JP2007507458A (pt)
AR (1) AR045957A1 (pt)
AU (1) AU2004280078B2 (pt)
BR (1) BRPI0414864A (pt)
CA (1) CA2538099A1 (pt)
MX (1) MXPA06003646A (pt)
PE (1) PE20050755A1 (pt)
TW (1) TW200520759A (pt)
WO (1) WO2005034916A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210787B2 (en) 2002-02-01 2009-04-23 Medinol Ltd. Phosphorus-containing compounds & uses thereof
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
CN101583347A (zh) 2006-11-14 2009-11-18 阿里亚德医药股份有限公司 口服制剂
WO2009022355A1 (en) * 2007-08-13 2009-02-19 Panacea Biotec Limited Extended release compositions comprising mycophenolate sodium and processes thereof
CN101969931A (zh) * 2008-03-05 2011-02-09 万能药生物有限公司 包含霉酚酸的调节释放药物组合物及其方法
NZ597118A (en) * 2009-06-25 2013-10-25 Dupont Nutrition Biosci Aps A method for increased expression of a variant lipolytic enzyme
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
KR101643219B1 (ko) * 2011-10-06 2016-07-27 노파르티스 아게 40-o-(2-히드록시)에틸-라파마이신을 포함하는 제약 조성물
WO2014059309A1 (en) * 2012-10-11 2014-04-17 Theravida, Inc. Pharmaceutical formulations of pilocarpine
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
WO2014167442A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
WO2016185443A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
BR112019010470A2 (pt) 2016-11-23 2019-09-10 Novartis Ag métodos de realce de resposta imune com everolimo, dactolisib ou ambos
BR112019019003A2 (pt) * 2017-03-13 2020-04-14 Okava Pharmaceuticals Inc métodos e composições para dispensação de agentes ativos de ácidos micofenólicos a mamíferos não humanos
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
US20240010618A1 (en) * 2021-12-23 2024-01-11 Glenmark Lofe Science Limited Process for the preparation of brivaracetam
WO2023224914A1 (en) * 2022-05-16 2023-11-23 Mayo Foundation For Medical Education And Research Assessing and treating caveolinopathy diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
BR9407728A (pt) * 1993-10-01 1997-02-12 Syntex Inc Suspensoes orais de altas doses de mofetil de microfenolato
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
JP2001505190A (ja) * 1996-10-14 2001-04-17 エフ・ホフマン―ラ ロシュ アーゲー 微粉状調製物の調製方法
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU4565000A (en) * 1999-05-10 2000-11-21 Novartis Ag Organic compounds
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
CN1615137A (zh) * 2002-01-10 2005-05-11 诺瓦提斯公司 用于预防和治疗血管疾病、包含雷帕霉素及其衍生物的药物递送***
EP1539157B1 (en) * 2002-09-18 2013-08-21 Trustees Of The University Of Pennsylvania Rapamycin for use in inhibiting or preventing choroidal neovascularization
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PE20050755A1 (es) 2005-11-28
AR045957A1 (es) 2005-11-16
US20070036857A1 (en) 2007-02-15
AU2004280078A1 (en) 2005-04-21
TW200520759A (en) 2005-07-01
EP1670437A1 (en) 2006-06-21
AU2004280078B2 (en) 2008-08-07
MXPA06003646A (es) 2006-06-05
CA2538099A1 (en) 2005-04-21
JP2007507458A (ja) 2007-03-29
WO2005034916A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
WO2006024479A3 (en) Pharmaceutical multiparticulate compositions comprising mycophenolic acid or mycophenolate sodium and combination compositions with rapamycin
BR0206955A (pt) Ligantes de receptores de canabinóides
BRPI0414492A8 (pt) solvato acetônico do dimetóxi docetaxel e seu processo de preparação
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
BR0011448A (pt) Imidazoquinolinas substituìdas por amida
EP2075011A3 (en) Prodrugs containing bio-cleavable disulfide linkers
EP2266623A3 (en) Prodrugs containing novel bio-cleavable linkers
GT200200122A (es) Imidazotriazinas
BR0210028A (pt) Agentes antibacterianos
ATE499372T1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
ATE491446T1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
BR0300709A (pt) Sal de perindopril e as composições farmacêuticas contendo o mesmo
BRPI0620229A8 (pt) formulação
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BR0315139A (pt) Agentes antibacterianos de tetraidroquinolina tricìclica
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
ECSP066564A (es) Formulaciones de tableta de liberación extendida de venlafaxina
TR200200310T2 (tr) Interlökin-5 inhibe eden 6-azaurasil türevleri.
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm
DK1970372T3 (da) Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina
TW200724145A (en) Substituted acrylamide derivatives and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.